Plasma costs anywhere from about $25 per donation at the collection center to well over $100,000 per year for a patient receiving plasma-derived therapies, depending on where in the supply chain you look. A liter of raw plasma is worth roughly $200 on the commercial market, but by the time it has been fractionated into immunoglobulins or clotting factors, shipped to a hospital, and infused into a patient, the price has multiplied many times over. The gap between what donors receive and what patients pay is one of the widest in modern medicine, driven by manufacturing complexity, safety requirements, and a global supply chain that leans heavily on a single country.
What Donors Get Paid
In the United States, where the vast majority of the world’s source plasma is collected, donors typically receive compensation for their time and inconvenience rather than a direct payment for the plasma itself. The going rate at most commercial plasma centers falls in the range of $30 to $75 per visit, with first-time donors and promotional bonuses sometimes pushing that higher. One analysis pegs the price of a liter of plasma at around $200 on the commercial market, with donors receiving roughly 20 to 30 percent of that figure in fees.1Annals of Blood. The blood feud: compensated versus non-compensated source plasma donations Since a single apheresis session typically yields somewhere around 600 to 900 milliliters, the per-visit payment tracks with that percentage.
Europe is a different landscape. Most European countries operate non-remunerated donation systems, relying on volunteer donors motivated by altruism. Only a handful offer financial compensation, and where it does exist, it ranges from roughly 10 to 35 euros per donation.2PubMed. Incentives for plasma donation Countries with a centralized collection model, where a single organization handles all plasma, usually do not pay donors at all. Countries with multiple competing collection organizations tend to use a wider mix of monetary and non-monetary incentives.2PubMed. Incentives for plasma donation
Whether donors should be paid remains a real ethical debate in transfusion medicine. Compensation attracts people who might not otherwise donate, but it can also deter people who are strongly motivated by altruism and feel that payment cheapens the act. Some researchers have argued that a combination of paid and unpaid systems could cover the widest range of potential donors.3Plasmatology. Plasmapheresis and Plasma Donation: Challenges in the Blood/Plasma Supply Chain In practice, though, the paid model has won out on volume. The United States, which relies almost entirely on compensated donation, produces about 70 percent of the world’s plasma supply.4PubMed Central. Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages
The Cost of Collecting Plasma
The donation is just the starting point. Getting plasma from a donor’s arm into a form that can be shipped to a fractionation plant carries its own costs, and those costs vary dramatically depending on how the plasma is obtained. There are two main routes: plasma can be recovered from whole-blood donations after the red cells and platelets are separated out, or it can be collected directly through apheresis, a process that returns the cellular components to the donor and keeps only the plasma.
A study examining these costs in a public health-care setting found that the estimated total cost per liter was about €113 for plasma recovered from whole blood and about €276 for plasma collected through dedicated apheresis.5PubMed Central. Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer When the plasma from whole blood donations was treated as a by-product (since the red cells were the primary reason for the donation), its cost dropped to just €26 per liter.5PubMed Central. Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer That gap matters because it reveals a basic tension in the economics of plasma: apheresis yields more plasma per session but costs more than twice as much per liter to perform.
Commercial plasma operations overwhelmingly use apheresis because it is the only way to collect enough volume to meet global demand for plasma-derived medicines. A single apheresis session yields several times more plasma than can be recovered from a standard whole-blood donation. But that efficiency comes at a price, and collection costs are a meaningful share of what patients eventually pay.
What Happens During Manufacturing
Once collected, source plasma is shipped in frozen form to fractionation plants, where it undergoes a complex industrial process to separate it into its component proteins. The standard approach, developed decades ago, uses cold ethanol precipitation to pull apart albumin, immunoglobulins, clotting factors, and other proteins. Modern versions of this process layer on additional steps for virus inactivation and purification, but the core chemistry has remained surprisingly consistent.
The single biggest cost input in fractionation is the plasma itself. Raw plasma typically accounts for the majority of production expenses, which is one reason why recombinant alternatives to plasma-derived products have struggled to compete on price despite their appeal on paper.6Biologicals. The past, present and future of blood plasma fractionation If you already need the plasma for one product, though, the economics shift. Fractionators have pushed hard over the years to extract at least three to four different products from each batch of plasma, spreading the raw material cost across multiple revenue streams.7Pharmaceuticals Policy and Law. Plasma proteins: Unique biopharmaceuticals – Unique economics
Manufacturing costs have climbed over time as safety requirements have become more demanding. Viral reduction steps, improved purification methods, and tighter quality controls all add expense. At the same time, these same steps can reduce the yield of finished product from each batch, meaning more plasma is needed to produce the same amount of medicine. The industry has responded with consolidation: a small number of very large fractionators now dominate global production, leveraging economies of scale to absorb these costs.7Pharmaceuticals Policy and Law. Plasma proteins: Unique biopharmaceuticals – Unique economics
Fresh Frozen Plasma at the Hospital
Not all plasma goes through fractionation. Fresh frozen plasma, or FFP, is used directly in hospitals to treat bleeding, replace clotting factors in emergency settings, and manage patients on blood thinners. It is one of the standard blood components alongside red cells and platelets, and it has its own distinct price structure.
Hospital blood-bank costs for FFP vary by country. One cost analysis at a cardiac surgery center found that the per-unit cost of fresh frozen plasma was in the range of $120 to $129, depending on the year studied.8PubMed Central. The cost of one unit blood transfusion components and cost-effectiveness analysis results of transfusion improvement program In the United States, however, the picture is more expensive when you account for the full chain of activities involved in actually getting that unit into a patient’s vein. A US hospital study found the total cost per unit of FFP transfused was about $410, and the total cost per patient receiving FFP averaged roughly $1,600.9PubMed. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital
What accounts for that leap from $120 to $410? The study broke it down and found that wasted products, in-hospital handling processes, and overhead costs accounted for about 90 percent of the total cost of FFP transfusions.9PubMed. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital FFP has a limited shelf life once thawed, and units that are thawed but not used must be discarded. Lab compatibility testing, nursing time, documentation, and monitoring all pile on. The product that left the blood bank at a modest unit price accumulates cost at every step before it reaches the patient.
Immunoglobulin Therapy and What Patients Face
The biggest dollar figures in the plasma economy come from manufactured plasma-derived therapies, and intravenous immunoglobulin (IVIg) is the flagship product. IVIg is pooled from thousands of donor plasma units, purified, and concentrated into a product used to treat a wide range of immune deficiencies and autoimmune conditions. It is the single largest driver of global plasma demand.
For patients with chronic conditions requiring ongoing IVIg treatment, the costs add up fast. In studies of chronic inflammatory demyelinating polyneuropathy, a nerve condition often treated with regular IVIg infusions, the immunoglobulin itself accounted for 51 to 67 percent of the total patient care costs.10PubMed Central. The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP Everything else, including doctor visits, other medications, and hospital stays, was secondary to the IVIg bill.
A direct look at the numbers comes from a comparison of IVIg treatment versus therapeutic plasma exchange (TPE) for Guillain-Barré syndrome, an acute neurological emergency. A standard course of five IVIg infusions totaling 2.0 grams per kilogram of body weight carried a direct cost of about $10,330. The alternative, a series of five plasma exchange procedures, cost about $4,640.11PubMed Central. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome For a 70-kilogram adult, IVIg was roughly 159 percent more expensive than plasma exchange, and hospitals treating with TPE instead of IVIg could save more than $5,680 per patient.11PubMed Central. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome That is just one acute episode. For patients who need IVIg every few weeks for months or years, annual costs can reach $30,000 to $100,000 or more, depending on body weight and dose.
Clotting Factor Therapies for Hemophilia
Hemophilia is where plasma-derived therapy costs reach their most extreme. Patients with hemophilia A lack a functional version of clotting factor VIII, and they need regular infusions to prevent dangerous bleeding. These concentrates can be manufactured either from donated plasma or through recombinant DNA technology, and the choice between the two has been one of the longest-running cost debates in hematology.
A US-based cost analysis comparing the two approaches in previously untreated patients with severe hemophilia A found that total cumulative costs over five years were about $835,000 per patient for plasma-derived factor VIII versus roughly $1,237,000 per patient for recombinant factor VIII. That translated to an average annual saving of about $80,500 per patient when using the plasma-derived product.12PubMed. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States A separate cost-utility analysis, conducted outside the US, found a similar pattern: recombinant factor VIII had higher costs but also somewhat better health outcomes, with mean treatment costs of about $37,600 versus $20,300 for the plasma-derived alternative.13PubMed Central. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A
Complications drive costs even higher. When hemophilia patients develop inhibitors, which are antibodies that neutralize the infused clotting factor, treatment becomes much more difficult and expensive. A Canadian study found that treating patients with inhibitors cost on average 2.25 times more than treating matched patients without inhibitors, though the increase was heavily skewed by a single patient who required frequent hospitalizations for severe bleeding.14PubMed. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada The financial unpredictability of hemophilia care is one reason it remains among the most expensive chronic conditions in the world.
Albumin and Other Plasma Products
Albumin is the most abundant protein in plasma and one of the cheapest plasma-derived products on a per-unit basis. Hospitals use it routinely to manage fluid balance in critically ill patients, particularly those with liver disease. While individual doses of albumin are far less expensive than IVIg or clotting factors, they still add up in patients who need repeated infusions.
A cost-effectiveness analysis across Germany, Italy, and Spain looked at albumin use for three common complications of advanced liver disease. Albumin was found to be less costly and more effective than alternatives like saline or gelatin for managing large-volume fluid removal. For spontaneous bacterial peritonitis, albumin combined with antibiotics was both more effective and less expensive than antibiotics alone in Germany and Italy, making it a dominant treatment strategy in economic terms. In Spain, the added cost was modest, translating to about €1,500 per life saved.15PubMed Central. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain Albumin is a reminder that not all plasma-derived therapies are budget-breaking. Some are genuinely cost-saving compared to the alternatives.
Why the United States Dominates Global Plasma Supply
The geography of the plasma market is strikingly lopsided. The United States supplies roughly 70 percent of the world’s plasma for manufacturing into therapies.4PubMed Central. Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages That figure has held roughly steady for years, and it makes the global supply chain unusually dependent on a single country’s collection infrastructure and regulatory environment.
The reason is straightforward: the US permits compensated plasma donation and has a well-developed commercial collection network, while most other countries either prohibit payment or offer minimal compensation. The result is that American donors, responding to financial incentives, donate plasma at far higher per-capita rates than donors anywhere else. Other countries have recognized this as a vulnerability. If a disruption were to hit US collection, whether from a pandemic, regulatory change, or economic shift, the consequences would ripple across the globe.16PubMed. Plasma is a strategic resource
Several European nations and other developed countries have explored ways to increase domestic plasma collection to reduce dependence on US imports, but progress has been slow. Shifting from a volunteer-only model to one that incorporates compensation involves political, ethical, and logistical challenges. Meanwhile, global demand for immunoglobulins and other plasma-derived medicines continues to rise as new clinical indications are approved and as developing countries improve access to treatment.
Where the Money Goes Between Donor and Patient
The gap between what a donor earns and what a patient pays is not the result of any single markup. It is the cumulative effect of dozens of steps, each of which adds cost. Collection centers must cover rent, staff, equipment, testing for infectious diseases, and the compensation paid to donors. Plasma must be frozen, stored, and shipped under controlled conditions to fractionation facilities that may be on a different continent. Fractionation itself involves multi-step chemical separation, virus inactivation, quality testing, and regulatory compliance at every stage. Finished products then enter a distribution chain involving wholesalers, hospital pharmacies, and insurance billing.
To put rough numbers on it: a donor receives perhaps $40 to $60 for the plasma in a single visit. That plasma, pooled with thousands of other donations, is fractionated into products that collectively generate far more than $200 per liter. A single course of IVIg therapy for one patient might require the equivalent of dozens of donations. A year of clotting factor therapy for one hemophilia patient consumes plasma from hundreds. By the time you multiply the raw material cost by the processing yield loss, the manufacturing overhead, the regulatory burden, and the distribution margin, the donor’s $50 contribution has been transformed into a product that bills in the thousands or tens of thousands of dollars.
This is not unique to plasma, but the magnitude of the multiplier is unusual in medicine. Most drugs are synthesized from chemical ingredients that cost pennies. Plasma-derived therapies start with a biological product that is expensive to collect, impossible to synthesize, and requires more processing per dose than almost any other pharmaceutical. The industry has improved efficiency over the decades, pulling more products from each batch and scaling up production, but the fundamental economics remain driven by the cost and limited supply of the raw material itself.
How Insurance and Out-of-Pocket Costs Vary
For patients, what you actually pay depends enormously on your insurance, your country, and your diagnosis. In the United States, most commercially insured patients with conditions like hemophilia or primary immunodeficiency have their plasma-derived therapies covered, but copays and coinsurance on specialty drugs can still run into thousands of dollars per year. Patients on high-deductible plans may face the full cost of their first infusions each year before coverage kicks in. Specialty pharmacy programs and manufacturer copay assistance cards offset some of this burden, but navigating them is its own part-time job.
In countries with single-payer or universal health systems, patients are generally shielded from direct costs for plasma-derived therapies, but the health system bears the full expense. That expense is significant enough to shape prescribing decisions. The finding that IVIg accounted for more than half of total care costs for chronic inflammatory neuropathy patients, for instance, has prompted ongoing research into whether cheaper alternatives like plasma exchange or subcutaneous immunoglobulin could reduce the system-level burden without sacrificing outcomes.10PubMed Central. The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP
Hemophilia patients in developing countries face a starker version of this problem. Without access to affordable plasma-derived or recombinant clotting factors, many receive inadequate treatment or none at all. The geographic concentration of plasma collection in the US and manufacturing in a few wealthy countries means that affordable supply simply does not reach large parts of the world. Efforts to build regional fractionation capacity in places like South America and Southeast Asia are underway, but they face the same fundamental bottleneck: plasma is expensive to collect, and collection depends on either well-funded volunteer programs or compensation systems that poorer countries struggle to sustain.
Recombinant Alternatives and Their Effect on Pricing
Recombinant products, manufactured using genetically engineered cell lines rather than human plasma, were supposed to break the supply constraint by removing the need for donors entirely. For clotting factors, recombinant versions have been available since the 1990s and are now the dominant treatment in wealthy countries. But they have not necessarily been cheaper. In the US, recombinant factor VIII for hemophilia A was substantially more expensive than plasma-derived factor VIII over a five-year treatment period, costing about $400,000 more per patient.12PubMed. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
The persistence of high prices for recombinant products reflects the reality that manufacturing biologics of any kind is expensive. Cell-culture production, purification, and quality control carry their own costs. And for immunoglobulins, no commercially viable recombinant alternative exists at all. You cannot engineer a single cell line to produce the thousands of different antibodies that make IVIg effective. Each batch of IVIg reflects the combined immune experience of the thousands of donors whose plasma went into it, and that diversity is the whole point. Until someone finds a way to replicate that synthetically, the global demand for donated plasma will continue to grow, and its price will be set by the willingness of donors to show up at collection centers, roll up their sleeves, and spend an hour hooked up to an apheresis machine for $50.